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Abstract Fabry disease (FD) is an X-linked inherited disease
due to alpha-galactosidase A (alpha-Gal A) deficiency and
characterized by lysosomal storage of globotriaosylceramide
(Gb3) and related neutral glycosphingolipids. Storage of these
substrates results in multisystem manifestations, including
renal failure, cardiomyopathy, premature myocardial infarc-
tions, stroke, chronic neuronopathic pain, gastrointestinal
disturbances, and skin angiokeratoma. Enzyme replacement
therapy (ERT) with recombinant human alpha-galactosidase
A (rh-alpha-Gal A) is now available for the treatment of FD
and in most patients results in clinical improvement or
stabilization. However, ERT efficacy may vary in different
tissues and its long-term effects remain to be defined. As a
strategy to improve the efficacy of ERT, we tested the
combination of rh-alpha-Gal A with the chaperone molecule
1-deoxynojirimycin (DGJ) in cultured FD fibroblasts with
negligible residual enzyme activity. Compared to the effects of
rh-alpha-Gal A alone, co-administration of DGJ and rh-alpha-
Gal A resulted in better correction (4.8 to 16.9-fold) of
intracellular alpha-Gal A activity, and increased amounts of
the enzyme within the lysosomal compartment. The clearance
of lyso-Gb3, one of the substrates stored in FD and a potent
inhibitor of alpha-Gal A, was also significantly improved with
the co-administration of DGJ and rh-alpha-Gal A. This study
provides additional evidence for a synergistic effect between
ERTand pharmacological chaperone therapy and supports the
idea that the efficacy of combination protocols may be
superior to ERT alone.
Introduction
Fabry disease (FD, OMIM 301500) is an X-linked inherited
disease due to alpha-galactosidase A (alpha-Gal A; EC
3.2.1.22) deficiency and characterized by lysosomal storage
of globotriaosylceramide (Gb3) and related neutral glyco-
sphingolipids (Germain, 2010). Storage of these com-
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pounds in vascular endothelia and in multiple organs
throughout the body results in progressive and potentially
life-threatening manifestations, including renal failure,
cardiomyopathy, premature myocardial infarctions, and
stroke. FD patients also present with chronic neuronopathic
pain, gastrointestinal disturbances, and the typical skin
angiokeratoma.
FD is one of the most common lysosomal storage
diseases with an estimated prevalence of approximately 1
in 100,000 (Meikle et al. 1999; Germain, 2010) although
this prevalence may be underestimated (Spada et al. 2006;
Lin et al. 2009). Studies in selected populations, such as
patients with unexplained left ventricular hypertrophy
(Nakao et al. 1995; Elliott et al. 2011) or with renal failure
(Nakao et al. 2003; Tanaka et al. 2005), clearly indicate that
in many FD patients non-specific signs and symptoms are
mistakenly attributed to other diseases.
Until the beginning of the 2000s the management of FD
patients was exclusively based on supportive therapies. In
2001, enzyme replacement therapy (ERT) with recombinant
human alpha-galactosidase A (rh-alpha-Gal A) was intro-
duced to treat FD (Eng et al. 2001; Schiffmann et al. 2000).
Two recombinant rh-alpha-Gal A preparations are presently
approved in Europe for ERT, agalsidase alpha (Replagal,
Shire Human Genetic Therapies), and agalsidase beta
(Fabrazyme, Genzyme Corporation). ERT results in sub-
strate clearance from vascular endothelia and in clinical
improvement or stabilization of disease (Mehta et al. 2009).
However, in several patients evidence of disease progres-
sion and persistence of Gb3 storage in other cells types,
such as podocytes and distal tubular cells (Thurberg et al.
2002), has been observed despite enzyme treatment. The
published evidence for clinical efficacy of ERT in FD has
been reviewed in a recent metanalysis (Lidove et al. 2010).
According to this study significant clinical benefits of ERT
have been demonstrated, mainly in patients at an early
phase of the disease, with beneficial effects on heart,
kidneys, pain, and quality of life. However, there is not
sufficient data to confirm the long-term clinical benefits of
ERT and to determine the optimal time to start treatment in
order to prevent irreversible organ damage. Thus, strategies
directed towards the improvement of the therapeutic action
of ERT or to the identification of alternative approaches for
the treatment of this disorder would be highly desirable.
In the recent years, several other approaches to treat
lysosomal storage diseases have been approved for clinical
use or have been tested in pre-clinical studies, including
hematopoietic stem cell transplantation, substrate reduction
therapy, pharmacological chaperone therapy (PCT), and
gene therapy. Among them, PCT seems a promising
strategy for the treatment of diseases due to protein
misfolding in general and specifically for lysosomal storage
diseases. This approach is based on the use of active site-
directed ligands (so called “chaperones”) that can provide
protection against misfolding and prevent the degradation
of mutated proteins with altered conformations. The first
studies on PCT in lysosomal storage diseases were actually
done in FD. Fan et al. (1999) showed that a competitive
inhibitor of alpha-Gal A, 1-deoxy-galactonojirimycin
(DGJ), effectively enhanced defective alpha-Gal A in FD
lymphoblasts, partially restoring the enzyme activity. Since
then the use of PCT has been proposed to enhance mutated
lysosomal enzyme residual activity in several other lyso-
somal storage disorders (Fan 2008; Parenti 2009).
A different and innovative use of chaperones was intro-
duced in a study that demonstrated a synergy between the
chaperone molecule N-butyl-deoxynojirimycin (NB-DNJ)
and ERT in another relatively prevalent lysosomal storage
disease, Pompe disease (PD, OMIM 232300), due to alpha-
glucosidase (GAA, EC 3.2.1.20) deficiency (Porto et al. 2009).
When recombinant human alpha-glucosidase (rh-GAA), was
administered to PD fibroblasts in combination with NB-DNJ
the lysosomal trafficking and maturation of rh-GAA im-
proved and intracellular GAA activity increased. A prelim-
inary experiment, reported in the same paper, suggested that
this synergy between ERT and a chaperone molecule was not
limited to PD, but could be extended to FD.
Here we provide formal demonstration in six FD
fibroblast cell lines that the combination of ERT and PCT
results in improved correction of alpha-Gal A activity and
in increased intracellular amounts of the recombinant
enzyme. Our results imply that this combination therapy
may represent a way to improve the efficacy of ERT in any
lysosomal storage disease treatable by this approach.
Materials and methods
Fibroblast cultures
Fibroblasts from male FD patients were derived from skin
biopsies after obtaining the informed consent of patients.
Normal age-matched control fibroblasts were available in
the laboratory of the Department of Pediatrics, Federico II
University of Naples. All cell lines were grown at 37°C
with 5% CO2 in Dulbecco’s modified Eagle’s medium
(Invitrogen, Grand Island, NY) and 10% fetal bovine serum
(Sigma-Aldrich, St Louis, MO), supplemented with 100 U/
ml penicillin and 100 mg/ml streptomycin. The cells were
used for the experimental procedures indicated below after
4–6 passages.
Reagents
The recombinant enzyme agalsidase-beta (Fabrazyme) was
from Genzyme (Naarden, the Netherlands). As source of
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enzyme we used the residual amounts of the reconstituted
recombinant enzyme prepared for the treatment of FD
patients at the Department of Nephrology, Federico II
University, Naples. The chaperones DGJ and NB-DNJ were
purchased from Sigma-Aldrich.
The anti alpha-Gal A primary antibody used for
immunofluorescence and western blot analysis was pur-
chased from Abnova, Heidelberg, Germany; the anti-beta-
actin mouse monoclonal antibody was from Sigma-Aldrich;
the anti-human LAMP2 mouse monoclonal antibody was
from Santa Cruz Biotechnology, Santa Cruz, CA. Anti-
rabbit and anti-mouse secondary antibodies conjugated to
Alexa Fluor 488 or 596 were from Molecular Probes,
Eugene, OR; HRP-conjugated anti-rabbit or anti-mouse
IgG were from Amersham, Freiburg, Germany. Labeling of
rh-alpha-Gal A was performed using the Alexa Fluor 546
labeling kit (Molecular Probes) according to the manufac-
turer instructions.
Incubation of fibroblasts with rh-alpha-Gal A and alpha-Gal
A assay
To study the rh-alpha-Gal A uptake and correction of alpha-
Gal A activity in FD fibroblasts, the cells were incubated
with 5 nmol/l rh-alpha-Gal A for 24 h, in the absence or in
the presence of 20 μmol/l DGJ. Untreated cells or cells
incubated with DGJ alone were used for comparison. Each
experiment was started 3–4 days after the last trypsiniza-
tion. After the incubation the cells were harvested by
trypsinization and disrupted by five cycles of freezing and
thawing. To inhibit the uptake of rh-alpha-Gal A the cells
were incubated with the recombinant enzyme in the
presence of 5 mmol mannose-6-phosphate (Sigma Aldrich).
Alpha-Gal A activity was assayed by using the fluoro-
genic substrate 4-methylumbelliferyl-alpha-D-galactopyra-
noside (Sigma-Aldrich). Twenty-five micrograms of protein
were incubated with 3 mmol/l concentrations of substrate
and 0.1 M N-acetyl-D-galactosamine in 0.2 mmol/l acetate
buffer, pH 4.5, for 60 min in incubation mixtures of 300 μl.
The reaction was stopped by adding 700 μl of glycine-
carbonate buffer, pH 10.7. Fluorescence was read at
365 nm (excitation) and 450 nm (emission) on a Turner
Biosystems Modulus fluorometer. Protein concentration in
cell homogenates was measured by the Bradford assay
(Biorad, Hercules, CA).
Western blot analysis
To study alpha-Gal A immunoreactive material, fibroblast
extracts were subjected to western blot analysis. The cells
were harvested, washed in phosphate-buffered saline,
resuspended in water, and disrupted by five cycles of
freeze-thawing. Equal amounts (20 μg protein) of fibroblast
extracts were subjected to sodium dodecyl sulfate poly-
acrylamide gel electrophoresis and proteins were trans-
ferred to PVD membrane (Millipore, Billerica, MA). An
anti-human alpha-Gal A antiserum were used as primary
antibody to detect alpha-Gal A polypeptides; to detect β-
actin, a monoclonal mouse antibody was used. Immunore-
active proteins were detected by chemiluminescence (ECL,
Amersham, Freiburg, Germany).
Immunofluorescence analysis and confocal microscopy
To study the distribution of alpha-Gal A and LAMP2, FD
fibroblasts grown on coverslips were fixed using methanol,
permeabilized using 0.1% saponin and blocked with 0.01%
saponin, 1% fetal bovine serum diluted in phosphate-
buffered saline for 1 h. The cells were incubated with the
primary antibodies, with secondary antibodies in blocking
solution and then mounted with vectashield mounting
medium (Vector Laboratories, Burlingame, CA). Samples
were examined with a Zeiss LSM 5 10 laser scanning
confocal microscope. We used Argon/2 (458, 477, 488, and
514 nanometers) and HeNe1 (543 nanometers) excitation
lasers, which were switched-on separately to reduce cross-
talk of the two fluorochromes. The green and the red
emissions were separated by a dichroic splitter (FT 560)
and filtered (515–540-nm bandpass filter for green and
>610-nm long pass filter for red emission). A threshold was
applied to the images to exclude ∼99% of the signal found
in control images.
Analysis of lyso-Gb3 in fibroblast extracts
The quantitative analysis of lyso-Gb3 in FD fibroblasts was
performed according to published methods, with slight
modifications (Boscaro et al. 2002) using liquid chroma-
trography coupled with electrospray ionization-tandem
mass spectrometry (LC-ESI-MS/MS). Retention time of
lyso-Gb3 was 0.65 min in a 2.80 min run. The detection of
the analytes of interest was achieved using a triple
quadrupole instrument operating in the multiple reaction
monitoring mode. The statistical significance of the effects
of DGJ and rh-alpha-Gal A on Lyso-Gb3 levels in
fibroblasts was evaluated by a chi-square test.
Results
The effects of the combination of DGJ and rh-alpha-Gal A
were studied in fibroblasts cell lines from six FD patients in
follow-up at the Department of Nephrology, Federico II
University. All patients had been molecularly characterized
(Table 1) and were on ERT with algasidase beta, with
stabilization of the disease clinical course.
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DGJ enhances rh-alpha-Gal A efficacy in cultured
fibroblasts from FD patients
To study the effect of the small-molecule chaperone DGJ
on rh-alpha-Gal A efficacy, FD fibroblasts were incubated
with rh-alpha-Gal A, with DGJ, or with both. After 24 h the
cells were harvested and the intracellular activity of alpha-
Gal A was measured. None of the cell lines showed
significant increases in baseline activity when incubated
with the chaperone alone, indicating that the GLA gene
mutations of these patients were non-responsive to PCT.
For the mutation p.R227Q this result is consistent with the
results of a screening of 75 mutations of the GLA gene
(Benjamin et al. 2009). The correction of alpha-Gal A
activity in the cells incubated with the recombinant enzyme
alone was variable among the different cells lines and
ranged from 19.9 to 80.6 nmoles 4-methylumbelliferone/
mg protein/hour.
When the cells where co-incubated with DGJ and rh-alpha-
Gal A we observed a highly improved correction of
intracellular activity. Increases in alpha-Gal A activity ranged
from 4.8 to 16.9-fold, compared to cells incubated with rh-
alpha-Gal A alone (Fig. 1a). The effect of the combination of
ERT and PCT in FD fibroblasts was much higher than that
observed in our previous study on the synergy of ERT and
chaperones in PD fibroblasts (Porto et al. 2009).
Patients 2 and 3, carrying the same genotype, responded
in a different way to the combination of rh-alpha-Gal A and
DGJ. In principle, this difference may be due to other
factors (genetic background, intracellular trafficking of
vesicles and of the mannose-6-phosphate receptors,
degree of substrate storage) that may alter the cellular
environment, vary in different cell lines and modify the
uptake of recombinant enzymes and their efficacy in
correcting the enzyme deficiency. This is well known
for other lysosomal diseases, such as PD (Fukuda et al.
2006; Cardone et al. 2008).
The enhancing effect of DGJ was not directed to the
endogenous defective alpha-Gal A. First, the cell lines
studied were from patients with mutations non-responsive
to the chaperone. Second, we observed an increase in the
amount of fluorochrome-labelled rh-alpha-Gal A in the
presence of DGJ, compared to cells incubated with
fluorescent rh-alpha-Gal A alone (Fig. 1b). By this
approach only the fluorescent exogenous enzyme is
detectable and variations in the intensity of fluorescence
reflect only the effects on the recombinant enzyme. Finally,
the enhancing effect of DGJ on rh-alpha-Gal Awas abolished
in the presence of mannose-6-phosphate (Fig. 1c).
DGJ increases intracellular amounts of rh-alpha-Gal A
Co-administration of DGJ and rh-alpha-Gal A resulted in
all cell lines in a substantial increase in the amount of
intracellular enzyme compared with cells treated with rh-
alpha-Gal A alone, suggesting improved intracellular
stability of the enzyme. A representative western blot
analysis of fibroblasts from patient 4 is shown in Fig. 2a.
The large increase in alpha-Gal A protein in cells treated
with rh-alpha-Gal A and DGJ, compared to the cells treated
with rh-alpha-Gal A alone, was consistent with the high
levels of alpha-Gal A enzyme activity obtained with the
combination therapy (Fig. 2a).
Confocal immunofluorescence studies showed increased
amounts of the fluorochrome-labeled enzyme, co-localizing
with the lysosomal marker LAMP2 (Fig. 2b).
The effect of DGJ on rh-alpha-Gal A is specific
To test whether the effect of chaperones on recombinant
enzymes is specific, we incubated one of the FD cell lines
with rh-alpha-Gal A in the presence of NB-DNJ, a known
chaperone for GAA, the enzyme deficient in PD. Con-
versely, we incubated PD fibroblasts with rhGAA in the
presence of DGJ. In both cases the inappropriate non-
specific chaperone had no enhancing effect on each of the
recombinant enzymes (Fig. 3). This indicates that for the
enhancing effect of chaperones on recombinant enzymes
specific molecular interactions between the drug and the
catalytic sites of each enzyme are required.
Table 1 GLA gene mutations in




1 6 p.A288D 4.86 Eng et al. 1994
2 4 Aberrant splicing IVS4+5 G>T 5.16 Okumiya et al. 1995
3 4 Aberrant splicing IVS4+5 G>T 6.5 Okumiya et al. 1995
4 3 c.452delA fsV164X 4.47 Not reported
5 5 p.R227Q 4.48 Eng et al. 1993;
Benjamin et al. 2009
6 6 c.946delG fsV316X 4.60 Gal 2010
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DGJ reduces lyso-Gb3 levels in FD cultured fibroblasts
It has been reported that, in addition to Gb3, other
secondary substrates accumulate in FD. One of them is
lyso-Gb3, a deacylated Gb3, that has been shown to
contribute to FD pathophysiology by inducing prolifer-
ation of smooth muscle cells and promoting cellular
storage. Due to the high structural similarity to Gb3,
lyso-Gb3 is a potent inhibitor of alpha-Gal A (Aerts et
al. 2008) and, in principle, may limit the efficacy of ERT
Fig. 1 a. FD fibroblasts were incubated with DGJ, rh-alpha-Gal A, or
DGJ plus rh-alpha-Gal A for 24 h. The cells were harvested and alpha-Gal
A was measured in the cell homogenates. In all cell lines co-
administration of DGJ and rh-alpha-Gal A resulted in improved
correction of intracellular activity, compared to cells treated with rh-
alpha-Gal A alone. In cell lines from patients 4, and 6 incubation of DGJ
alone caused a modest increase of enzyme activity. b. FD fibroblasts
(patient 4) were incubated with fluorochrome-labelled rh-alpha-Gal A in
the absence and in the presence of DGJ. By this approach only the
exogenous enzyme is visible (red) at the confocal immunofluorescence
analysis. Co-incubation of labelled rh-alpha-Gal A with the chaperone
increased the amount of enzyme detectable intracellularly, compared to
that obtained in cells treated with rh-alpha-Gal A alone. c. The
enhancing effect of DGJ on rh-alpha-Gal A was abolished by co-
incubation of the cells with mannose-6-phosphate
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in FD patients. We tested the effects of the combination of
rh-alpha-Gal A and DGJ on intracellular lyso-Gb3 levels
in four of the FD fibroblast cell lines (patients 1, 3, 4 and
5). All cell lines showed detectable levels of lyso-Gb3
under baseline conditions. Incubation of these cells for
24 h with rh-alpha-Gal A substantially reduced (by 36.8%)
lyso-Gb3 levels (Fig. 4). Co-administration of DGJ and
rh-alpha-Gal A resulted in improved clearance of the
substrate (with average decrease of 51.0% with respect to
untreated cells), indicating better efficacy of the combina-
tion regimen. The reduction of lyso-Gb3 after incubation
of the cells with DGJ alone (18.9%) was not statistically
significant.
Discussion
For its prevalence and for the heavy impact of the disease
on patients’ life expectancy and quality of life, FD should
be considered an important medical and social problem.
The introduction of ERT for the treatment of FD has been a
major advancement and has improved substantially the
outcome of patients. However, like for several other
lysosomal storage diseases, also for FD ERT shows
limitations and strategies directed towards the improvement
of ERT efficacy would be most welcome.
We have shown for another lysosomal disorder that one
such strategy may be based on the combination of ERT
Fig. 2 a. Western blot analysis
of GLA in fibroblasts from pa-
tient 4. The cells treated with rh-
alpha-Gal A and DGJ show a
large increase in alpha-Gal A,
compared to the cells treated with
rh-alpha-Gal A alone. b. Confo-
cal immunofluorescence analysis
of FD fibroblasts (same patient)
treated with a fluorochrome-
labelled rh-alpha-Gal A. The
cells treated with the co-
administration of rh-alpha-Gal A
and DGJ showed improved co-
localization of the fluorochrome-
labeled enzyme with the lyso-
somal marker LAMP2, indicating
increased amounts of the enzyme
in the lysosomal compartment
Fig. 3 Effect of different chap-
erones on recombinant enzymes.
FD cell lines incubated with rh-
alpha-Gal A in the presence of
NB-DNJ, a known chaperone
for GAA, showed no enhance-
ment of GLA activity. Similarly,
no effect was seen on GAA
activity in PD fibroblasts treated
with GAA in the presence of
DGJ. GAA activity was assayed
as described in Porto et al.
(2009)
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with pharmacological chaperones (Porto et al. 2009). The
potential of this approach was studied in PD fibroblasts, in
the animal model of this disorder, and, in a preliminary
experiment, in FD fibroblasts. Similar results were obtained
also in cultured Gaucher disease cells (Shen et al. 2008).
Pharmacological chaperones have been traditionally
studied for their effects on mutated enzymes. A clinical
trial based on this concept has been completed (Trial
NCT00214500 at http://clinicaltrials.gov) and showed
encouraging results.
On the other hand the enhancing effect of chaperones on
wild-type recombinant enzymes used for ERT is intriguing
and still not clear. This effect may imply that a substantial
fraction of the recombinant enzyme, during its transit to
lysosomes, is prone to degradation and does not reach its
final destination. Specific interactions between pharmaco-
logical chaperones and recombinant enzymes may favour
the most stable conformations of the enzymes, protect them
in the cells and tissues, and prevent their degradation.
In this study we have provided additional evidence
supporting the potential of the combination of ERT and
PCT. We performed our studies in cultured fibroblasts.
Although these cells are not the preferred target of therapy
in Fabry disease, fibroblasts were used because these cells
can be obtained by non-invasive techniques and can be
easily manipulated in culture.
We showed that co-administration of DGJ and rh-alpha-
Gal A to FD fibroblasts results in better correction of
intracellular alpha-Gal A activity. We provided evidence
that this effect is directed towards the exogenous recombi-
nant enzyme used for ERT and not on the endogenous
defective enzyme. This concept is supported by the
observation of an improved correction of alpha-Gal A
activity in cell lines derived from patients with mutations
that are unresponsive to the chaperone, by the detection of
the enhancing effect on a fluorochrome-labelled rh-alpha-
Gal A, and by the fact that the enhancing effect of DGJ on
rh-alpha-Gal A was abolished in the presence of mannose-
6-phosphate.
Western blot analysis studies demonstrated the presence
of increased amounts of alpha-Gal A protein in cells.
Confocal fluorescence microscopy showed that the in-
creased amounts of rh-alpha-Gal A largely co-localized
with the lysosomal marker LAMP2. These results may
indicate improved stability of the recombinant enzyme,
facilitated delivery to the lysosomal compartment, or both.
Obtaining substantial amounts of alpha-Gal A in lysosomes
is an important therapeutic goal that may result in improved
clearance of stored substrates.
In principle, the enhancement of rh-alpha-Gal efficacy
by DGJ may be non-specific and not dependent on its
chaperone effect. To address this point we incubated cells
from a patient with another lysosomal disease, PD, with rh-
GAA and DGJ, and viceversa FD cells with rh-alpha-Gal A
and NB-DNJ, a chaperone for GAA. The use of the
inappropriate chaperone did not result in an enhancing
effect. This indicates that none of the drugs cause non-specific
effects, such as perturbations on the cellular mechanisms
controlling vesicle trafficking or protein homeostasis, and that
specific interactions between the chaperone molecule
and the enzyme (likely within the catalytic domain) are
required for the synergistic effect to take place.
The increases in alpha-Gal A activity observed in our FD
cells were impressive, and much higher than those seen in
PD. This might imply that in FD cells a large amount of the
recombinant enzyme provided for ERT is degraded or that
part of the enzyme, after uptake and trafficking to
lysosomes, remains functionally inactive. Incubation of
cells with rh-alpha-Gal A and DGJ reduced the levels of
lyso-Gb3, a well-known and potent inhibitor of alpha-Gal
A (Aerts et al. 2008). This effect may thus contribute to the
improved correction of alpha-Gal A activity observed in FD
fibroblasts and explain the massive rh-alpha-Gal A en-
hancement in the presence of DGJ.
In conclusion, this study provides additional evidence
for a synergistic effect between ERT and PCT and supports
the idea that the efficacy of combination protocols may be
superior to ERT alone. Although these studies were done in
vitro and require further confirmation in vivo, our results
Fig. 4 Effects of the combination of rh-alpha-Gal A and DGJ on
intracellular lyso-Gb3 levels in four FD fibroblast cell lines (patients
1, 3, 4 and 5). All cell lines showed detectable levels of lyso-Gb3
under baseline conditions. After incubation for 24 h with rh-alpha-Gal
A lyso-Gb3 levels were significantly reduced. Co-administration of
DGJ and rh-alpha-Gal A resulted in improved clearance of the
substrate (with average decrease of 51.0% with respect to untreated
cells), indicating better efficacy of the combination regimen
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hold promise for the treatment of FD patients and suggest
that this approach can be extended to any other LSD for
which ERT and chaperones are available.
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